Category: Side Effect: Cancer (melanoma, leukemia, lymphoma, pancreatic)
-
Dupixent Lawsuits Being Filed for Patients: Medical Information and Legal Allegations
These Dupixent Cases Involving T-cell Lymphoma Cancer Are Against Regeneron Pharmaceuticals and Sanofi-Aventis (Posted by Tom Lamb at Drug Injury Watch) We are currently investigating possible Dupixent lawsuits for patients who were diagnosed with a relatively rare…
-
Dupixent Drug Injury Lawsuits For Patients Diagnosed With CTCL Cancer
Cutaneous T-cell Lymphoma (CTCL) Cancer Includes Mycosis Fungoides And Sézary Syndrome (Posted by Tom Lamb at Drug Injury Watch) A growing body of medical evidence showing an association between Dupixent and cutaneous T-cell lymphoma (CTCL) has given…
-
Ozempic Side Effects: Gallbladder Diseases, Thyroid Cancer, And Suicidal Thoughts
Diabetes and Weight-Loss Drug Ozempic Getting Scrutiny From European Drug Safety Regulator EMA ***See also: Ozempic Severe Gastric Side Effects Include Stomach Paralysis, Gastroparesis, And Intestinal Blockages (Posted by Tom Lamb at Drug Injury Watch)…
-
Off-Topic Alert: Breast Implants Lymphoma Cancer ALCL Case Numbers Increasing Rapidly in the US
New Estimates Reported in July 2022 Medical Journal Article Reveal BIA-ALCL is Diagnosed More Often as Time Goes On (Posted by Tom Lamb at Drug Injury Watch) A research letter published July 21, 2022 in…
-
Multiple Sclerosis (MS) Drugs Gilenya and Ocrevus Associated With a Higher Likelihood of Melanoma Skin Cancer
Other MS Treatments Such as Lemtrada and Mayzent May Have an Increased Risk of Basal Cell Carcinoma and Squamous Cell Carcinoma (Posted by Tom Lamb at Drug Injury Watch) An analysis of skin cancers reported…
-
JAK Inhibitors Safety Review by European Drug Regulator EMA Announced in February 2022
Xeljanz, Rinvoq, and Olumiant as Treatments for Inflammatory Disorders Have Been Under Scrutiny by FDA in the US (Posted by Tom Lamb at Drug Injury Watch) In December 2021 there was a notable JAK inhibitors…
-
Xeljanz Safety Study Final Data Details the Increased Risks of Cancers and Major Adverse Cardiovascular Events
January 2022 Medical Journal Article Presents Full Set of Findings for the Xeljanz "ORAL Surveillance" Trial Which Started in 2014 (Posted by Tom Lamb at Drug Injury Watch) One year ago Pfizer released some preliminary…
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…